CD86 antibody
Principal name
CD86 antibody
Alternative names for CD86 antibody
CD28LG2, Activation B7-2 antigen, B70, BU63, B7.2, FUN-1, T-lymphocyte activation antigen CD86, CTLA-4 counter-receptor B7.2
Ncbi ID
NP_062261.3, NP_008820.3, NP_064466.1, 9606, NP_062261, 10090, NP_008820, AAH40261.1, NM_020081, NM_019388, NM_006889, NM_001206924
Available reactivities
Available hosts
Available applications
Flow Cytometry (F), Frozen Sections (C), Immunoprecipitation (IP), Enzyme Immunoassay (E), ELISA (detection) (E(detection)), Western blot / Immunoblot (WB), Functional assay (FN), Immunocytochemistry/Immunofluorescence (ICC/IF), Paraffin Sections (P)
Background of CD86 antibody
B7-1 and B7-2 are transmembrane glycoproteins of the immunoglobulin superfamily that are expressed, along with the receptors CD28 and CTLA4, by antigen-presenting cells, and along with these receptors, constitute crucial co-stimulatory pathways for T and B cell regulatory responses. As members of the B7 family, B7-1 and B7-2 play principal roles in immunity, activating immune response and maintaining immune tolerance through engagement with CD28 and CTLA4. Co-stimulatory signals generated by B7-1 and B7-2 interactions with CD28 serve to stimulate T cell activation and prevent anergy through the amplification of T cell receptor (TCR) signaling. In contrast, interactions of the ligands with CTLA-4 serves to maintain T cell homeostasis and self-tolerance through the disruption of stimulatory signaling from B7 isoform bound CD28 complexes, and by inducing powerful inhibitory signals in T cells. B7-1 plays an important role in immune response through its amplification and regulation of T cell activity at peripheral inflammation sites. B7-1, like CTLA-4, is, however, only poorly expressed on resting dendritic cells, and its up-regulation is, therefore, considerably delayed upon immune activation. Conversely, B7-2 and CD28 are constitutively expressed by resting hematopoietic and T cells, respectively, and as a result are able to rapidly induce up-regulation upon immune activation, making them critical to the early co-stimulatory signaling of immune response. Both B7-1 and B7-2 have been shown to demonstrate co-stimulatory activity in T-cell proliferation in vitro and elicit enhanced antitumor immune response in vivo.
General readings
1. Hathcock, K., G. Laszlo, C. Pucello, O. Linsley, and R.J. Hodes. 1994. J. Exp. Med. 180:631.
2. Freeman, G.J., F. Borriello, R.J. Hodes, H. Reiser, K.S. Hathcock, G. Laszlo, A.J. McKnight, J. Kim, L. Du, D.B. Lombard, G.S. Gray, L.M. Nadler,
and A.H. Sharpe. 1993. Science 262:907.
3. Inaba, K. M. Witmer-Pack, M. Inaba, K.S. Hathcock, H. Sakuta, et al. 1994. J. Exp. Med. 180:1849.
4. Larsen, C.P., S.C. Ritchie, R. Hendrix, P.S. Linsley, K.S. Hathcock, R.J. Hodes, R.P. Lowry, and T.C. Pearson. 1994. J. Immunol. 152:5208.
5. Hathcock, K.S., G. Laszlo, C. Pucillo, P. Linsley, and R.J. Hodes. 1994. J. Exp. Med. 180:631.
6. Laszlo, G., K.S. Hathcock, H.B. Dickler, and R.J. Hodes. 1993. J. Immunol. 150:5252.
7. Hathcock, K., G. Laszlo, H. Dickler, J. Bradshaw, P. Linsley, and R Hodes. 1993. Science 262:905.
8. Thompson, C.B. 1995. Cell 978:982.
9. June, C.H., J.A. Bluestone, L.M. Nadler, and C.B. Thompson. 1994. Immuol. Today 15:321.
10. Han, S. et. al. 1995. J. Immunol. 155:556.












Primary Antibodies
| Catalog No. | Host | Iso. | Clone | Pres. | React. | Applications | |
|---|---|---|---|---|---|---|---|
| TA320296 | CD86 antibody |
||||||
| Rat Anti-Mouse CD86 (B7-2) Purified (100 ug) | |||||||
![]() |
Rat | GL1 | Purified | Ms | F, IP, P |
0.1 mg /
€195.00
|
|
| OriGene Technologies, Inc. | |||||||
| TA320298 | CD86 antibody |
||||||
| Rat Anti-Mouse CD86 (B7-2) Purified (100 ug) | |||||||
![]() |
Rat | PO3.1 | Purified | Ms | F |
0.1 mg /
€195.00
|
|
| OriGene Technologies, Inc. | |||||||
| TA326991 | CD86 antibody |
||||||
| CD86 Rabbit Polyclonal Antibody | |||||||
![]() |
Rabbit | IgG | Purified | Hu, Ms | WB |
0.1 mg /
€335.00
|
|
| OriGene Technologies, Inc. | |||||||
+1 additional image |
|||||||
| AM05571FC-N | CD86 antibody |
||||||
![]() |
Rat | IgG2b | PO3 | FITC | Ms | F |
0.1 mg /
€400.00
|
| OriGene Technologies GmbH | |||||||
| AM05571RP-N | CD86 antibody |
||||||
![]() |
Rat | IgG2b | PO3 | PE | Ms | F |
100 Tests /
€480.00
|
| OriGene Technologies GmbH | |||||||
| AM05571RP-T | CD86 antibody |
||||||
![]() |
Rat | IgG2b | PO3 | PE | Ms | F |
25 Tests /
€220.00
|
| OriGene Technologies GmbH | |||||||
| AM06519SU-N | CD86 antibody |
||||||
![]() |
Mouse | IgG1 | 1B3 | Ascites | Hu | E, WB |
0.1 ml /
€380.00
|
| OriGene Technologies GmbH | |||||||
| AM08053AC-N | CD86 antibody |
||||||
![]() |
Rat | IgG2a | GL1 | APC | Ms | F |
0.1 mg /
€360.00
|
| OriGene Technologies GmbH | |||||||
| AM08053BT-N | CD86 antibody |
||||||
![]() |
Rat | IgG2a | GL1 | Biotin | Ms | F |
0.5 mg /
€330.00
|
| OriGene Technologies GmbH | |||||||
| AM08053FC-N | CD86 antibody |
||||||
![]() |
Rat | IgG2a | GL1 | FITC | Ms | F |
0.5 mg /
€360.00
|
| OriGene Technologies GmbH | |||||||
| AM08053LE-N | CD86 antibody |
||||||
![]() |
Rat | IgG2a | GL1 | Low Endotoxin | Ms | F |
0.5 mg /
€380.00
|
| OriGene Technologies GmbH | |||||||
| AM08053PU-N | CD86 antibody |
||||||
![]() |
Rat | IgG2a | GL1 | Purified | Ms | C, F, FN, IP |
0.5 mg /
€310.00
|
| OriGene Technologies GmbH | |||||||
| AM08053RC7-N | CD86 antibody |
||||||
![]() |
Rat | IgG2a | GL1 | PE-Cy7 | Ms | F |
0.1 mg /
€360.00
|
| OriGene Technologies GmbH | |||||||
| AM08053RP-N | CD86 antibody |
||||||
![]() |
Rat | IgG2a | GL1 | PE | Ms | F |
0.2 mg /
€380.00
|
| OriGene Technologies GmbH | |||||||
| AM08053RP-S | CD86 antibody |
||||||
![]() |
Rat | IgG2a | GL1 | PE | Ms | F |
0.1 mg /
€300.00
|
| OriGene Technologies GmbH | |||||||
| AM08084AC-N | CD86 antibody |
||||||
![]() |
Rat | IgG2b | 2D10 | APC | Ms | F |
0.1 mg /
€360.00
|
| OriGene Technologies GmbH | |||||||
| AM08084BT-N | CD86 antibody |
||||||
![]() |
Rat | IgG2b | 2D10 | Biotin | Ms | C, F, IP |
0.5 mg /
€350.00
|
| OriGene Technologies GmbH | |||||||
| AM08084FC-N | CD86 antibody |
||||||
![]() |
Rat | IgG2b | 2D10 | FITC | Ms | C, F |
0.5 mg /
€360.00
|
| OriGene Technologies GmbH | |||||||
+1 additional image |
|||||||
| AM08084LE-N | CD86 antibody |
||||||
![]() |
Rat | IgG2b | 2D10 | Low Endotoxin | Ms | C, F, FN, IP |
0.5 mg /
€380.00
|
| OriGene Technologies GmbH | |||||||
| AM08084PU-N | CD86 antibody |
||||||
![]() |
Rat | IgG2b | 2D10 | Purified | Ms | C, F, FN, IP |
0.5 mg /
€310.00
|
| OriGene Technologies GmbH | |||||||



















+1 additional image


